Lee’s Pharm Begins Novel Liver Cancer Drug Trial

Lee’s Pharmaceutical Holdings Limited (HK:0950) has released an update.

Lee’s Pharmaceutical Holdings Limited has announced the initiation of a Phase I clinical trial for AU409, a novel oral treatment for advanced liver cancer developed by Auransa and manufactured by the Group’s subsidiary. The trial, which marks the first human study of AU409 in Asia, is focused on patients who have not responded to standard treatments and aims to establish the drug’s safety, dosage, and preliminary efficacy. Results from the trial, conducted at Queen Mary Hospital in Hong Kong, are anticipated to influence new drug registration in China.

For further insights into HK:0950 stock, check out TipRanks’ Stock Analysis page.